Research dossier
Clinical research on ALA
8 trials reviewed across 2 indications.
Strongest evidence
Diabetic peripheral neuropathy — symptomatic relief
Mechanism
ALA scavenges reactive oxygen species, regenerates other antioxidants (glutathione, vitamins C and E), and chelates redox-active metals. In diabetic nerves, oxidative stress drives axonal damage — ALA addresses an upstream cause, not just symptoms.
The most evidence-backed indication for any antioxidant supplement. ALADIN, SYDNEY 2, and the Han meta-analysis converge on 600 mg/day reducing pain, burning, and paresthesia in diabetic neuropathy. NATHAN 1 ran for 4 years and showed clinical-symptom benefit. IV ALA is a European prescription standard for diabetic polyneuropathy. Oral ALA at 600 mg/day is the home-use equivalent.
Effect sizes are largest in symptomatic diabetic neuropathy. Do not extrapolate to non-diabetic neuropathy or general nerve health — the trials are tightly bounded.
Trials cited
ALADIN — IV alpha-lipoic acid for diabetic neuropathy
positive · RCT
Ziegler et al., 1995, Diabetologian=328Multicenter RCT in 328 type 2 diabetics with symptomatic neuropathy. Three weeks of 600 mg IV ALA daily reduced TSS significantly versus placebo, with an 82.5% response rate vs 57.6% for placebo. The 100 mg arm showed no benefit and 1,200 mg added side effects without extra efficacy. Established the 600 mg/day dose anchor that every later trial used.
IV administration — bypasses oral absorption variability. The translation to oral dosing is not 1:1.
SYDNEY 2 — oral alpha-lipoic acid dose-finding for neuropathy
positive · RCT
Ziegler et al., 2006, Diabetes Caren=181Four-arm dose-finding RCT in 181 patients. Every active dose beat placebo on TSS (51% reduction at 600 mg vs 32% on placebo). 1,200 mg and 1,800 mg added side effects without proportional benefit. Authors concluded 600 mg/day oral ALA gives the best risk-benefit ratio — the dose every neuropathy product is now anchored to.
NATHAN 1 — 4-year ALA for diabetic polyneuropathy
mixed · RCT
Ziegler et al., 2011, Diabetes Caren=460The longest ALA trial ever run — 4 years, 460 patients on 600 mg/day oral. Failed the composite primary endpoint (NIS-LL + seven neurophysiology tests) but improved clinical neuropathy impairment scores and patient-reported symptoms. Safety profile across 4 years was clean, which matters when neuropathy treatment is a multi-year commitment.
Primary endpoint was negative; secondary endpoints were positive. Authors framed this as 'clinically meaningful improvement,' but the trial would not pass a strict drug-approval primary-endpoint review.
Han meta-analysis — ALA for diabetic peripheral neuropathy
positive · Meta-analysis
Han, Bai, Liu & Hu, 2012, European Journal of EndocrinologyPooled 15 RCTs of alpha-lipoic acid for diabetic peripheral neuropathy. ALA significantly improved both nerve conduction velocity and patient-reported symptom scores versus control. The IV-dosed trials drove most of the effect; oral data were thinner and less consistent.
Authors flagged methodological quality across the pooled trials as variable. Most of the strong signal came from short, IV-dosed studies — generalization to oral home use is partial.
ALADIN III — oral follow-on after IV induction
mixed · RCT
Ziegler et al., 1999, Diabetes Caren=509509 patients tested whether oral ALA could maintain the gains of IV induction. The 3-week IV phase reproduced the ALADIN signal, but the 6-month oral follow-on did not separate from placebo on TSS to a clinically meaningful degree. Oral 1,800 mg/day racemic ALA simply was not enough to maintain the IV benefit.
Used racemic oral ALA. Modern R-isomer products at the same total dose deliver roughly twice the active drug.
Glycemic control in T2D and metabolic syndrome
Mechanism
ALA enhances insulin-stimulated glucose uptake in skeletal muscle by activating the insulin signaling cascade and improving GLUT4 translocation. Mitochondrial cofactor activity for pyruvate dehydrogenase complements the insulin-sensitizing effect.
Across 24 RCTs in the Akbari 2018 pool, oral ALA reduced fasting glucose, insulin, HOMA-IR, and HbA1c. The Kucukgoncu meta-analysis adds a modest 1.27 kg weight benefit. Real signal, but the effect sizes are smaller than first-line glucose-lowering drugs — adjunct, not replacement.
Strongest in adults with documented metabolic dysfunction. Negligible benefit in metabolically healthy individuals.
Ansar — ALA for glycemic control in T2D
positive · RCT
Ansar et al., 2011, Saudi Medical Journaln=57Small RCT in 57 type 2 diabetics. 300 mg/day oral ALA over 8 weeks reduced fasting glucose, post-prandial glucose, and HOMA-IR insulin resistance versus placebo, with a glutathione peroxidase rise consistent with antioxidant action. Clean trial but small — feeds the bigger metabolic meta-analyses.
Small sample, single center, short duration. The effect size is what fed Akbari's pooled estimate, not a definitive standalone result.
Akbari meta-analysis — ALA for glucose and lipids in metabolic disease
positive · Meta-analysis
Akbari et al., 2018, MetabolismPooled 24 RCTs of oral alpha-lipoic acid in metabolic disease. Significant reductions in fasting glucose (SMD −0.54), insulin, HOMA-IR, and HbA1c, plus modest improvements in triglycerides and total cholesterol. Effect on glucose is real and replicated — but smaller than first-line glucose-lowering medication and not enough to replace one.
Large heterogeneity across pooled doses, durations, and populations. Translates to 'reliably better than placebo on labs,' not 'matches metformin.'
Kucukgoncu meta-analysis — ALA for body weight
positive · Meta-analysis
Kucukgoncu, Zhou, Lucas & Tek, 2017, Obesity ReviewsPooled 10 randomized double-blind placebo-controlled trials of oral alpha-lipoic acid. Mean weight loss was 1.27 kg greater than placebo and BMI dropped by 0.43 kg/m². Statistically real, clinically minor — call it a tail benefit, not a weight-loss strategy.
1.27 kg over 2–24 weeks is the kind of effect size that disappears under any meaningful diet variation. Not a substitute for caloric deficit.
4 forms of ALA compared
R-alpha lipoic acid (R-ALA)
The biologically active stereoisomer — roughly 2× the activity of racemic ALA per mg
Best forDiabetic neuropathy, glycemic support, mitochondrial use casesWhat your enzymes actually use. Less stable than the sodium salt form, so look for nitrogen-flushed packaging or a sodium R-lipoate version.
Bio-Enhanced® R-Lipoic Acid
Sodium R-lipoate (Na-RALA)
Stabilized R-ALA — same biological activity, far better shelf life and absorption
Best forPremium R-ALA delivery for serious daily useIf you are buying R-ALA for a multi-year protocol (diabetic neuropathy, metabolic support), this is the form to use. Free R-ALA degrades; the sodium salt does not.
Racemic alpha-lipoic acid (50% R + 50% S)
Half the bottle is biologically inactive S-isomer ballast
Best forMost retail ALA products. The dose used in ALADIN and SYDNEY 2 was racemic — but at 600 mg/day, half of that is wasted.The clinical trial doses for racemic ALA effectively deliver about 300 mg of active R-isomer. If you are taking racemic ALA at 300 mg/day expecting clinical effect, the actual active dose is closer to 150 mg.
Alpha-lipoic acid (unspecified isomer)
Default to racemic — assume 50% active
Best forGeneric supplement label. Without an R- prefix or 'sodium R-lipoate' callout, treat as racemic.Empty-stomach dosing improves absorption — food roughly halves bioavailability.
Side effects and drug interactions
Side effects
GI upset (nausea, abdominal discomfort)
Common · ≥1,200 mg/day
Most common at higher doses, particularly 1,200–1,800 mg/day. Empty-stomach dosing increases GI side effects in sensitive individuals.
Skin rash and itching
Uncommon
Reported in a small fraction of trial participants. Usually mild and self-limiting.
Hypoglycemia
Uncommon
ALA's insulin-sensitizing action can stack with antidiabetic medication and produce low blood sugar. Most relevant in adults already on metformin, sulfonylureas, or insulin.
Biotin status reduction
Uncommon · Long-term ≥600 mg/day without biotin co-supplementation
ALA structurally resembles biotin and competes with it at intestinal transporters. Long-term high-dose use has been associated with biotin insufficiency in case reports.
Insulin autoimmune syndrome (Hirata disease)
Rare
Rare case reports of ALA-triggered insulin autoantibodies causing severe spontaneous hypoglycemia. Risk is associated with HLA-DR4 allele, more common in East Asian populations.
Acute liver injury (case reports)
Rare
Rare hepatotoxicity reports, almost always reversible on discontinuation. Causality is debated — most cases involve poly-supplementation.
Drug interactions
Combined-effect risk
insulinmetforminsulfonylureas (glipizide, glyburide)GLP-1 agonistsSGLT2 inhibitorsALA's insulin-sensitizing effect adds to prescription glucose-lowering action and can drive hypoglycemia.
Monitor blood glucose closely when starting ALA on diabetic medications. Discuss with prescriber before adjusting doses.
Reduces nutrient status
levothyroxineALA can modestly lower active thyroid hormone (T3) and may interfere with levothyroxine's effect. Mechanism is not fully characterized.
If you are on thyroid replacement and start ALA, recheck TSH at 6–8 weeks. Separate dosing from levothyroxine by at least 4 hours.
Reduces nutrient status
biotin (long-term)ALA competes with biotin at intestinal transporters. Long-term high-dose ALA may reduce biotin status.
On chronic ALA use, consider 30–100 mcg/day biotin co-supplementation — especially relevant for hair, skin, and nail-focused users.
Other
chemotherapy agents (general)ALA's antioxidant effect may theoretically interfere with reactive-oxygen-species-dependent chemotherapy mechanisms. Evidence is mixed and mostly preclinical.
Do not start or continue ALA during active chemotherapy without oncology approval.
Other critical caveats
- Take on an empty stomach. Food roughly halves ALA absorption. The clinical-trial doses assume fasted dosing — eating with the supplement undoes a meaningful fraction of the dose.
- Racemic 50/50 ALA wastes half your money on an inactive S-isomer. If neuropathy or metabolic effect is the goal, buy R-ALA or sodium R-lipoate and dose accordingly.
- Diabetics on insulin, sulfonylureas, or metformin: monitor glucose closely when starting ALA. The hypoglycemia risk is real and additive.
- Long-term high-dose ALA without co-supplemented biotin can drift you into biotin insufficiency. Add 30–100 mcg biotin if you are on ALA daily for more than a few months.
- Rare but documented insulin autoimmune syndrome (Hirata disease) — if you are East Asian and develop unexplained hypoglycemia on ALA, stop and get tested for insulin autoantibodies.
Frequently asked
Does alpha-lipoic acid actually work for nerve pain?
For diabetic peripheral neuropathy specifically, yes — the evidence is among the strongest of any supplement. ALADIN (1995), SYDNEY 2 (2006), NATHAN 1 (2011), and the Han 2012 meta-analysis all support 600 mg/day for reducing pain, burning, and paresthesia. IV ALA is a European prescription standard. Do not extrapolate this to non-diabetic neuropathy — the trials are tightly limited to diabetic nerve damage.What's the difference between R-ALA and regular alpha-lipoic acid?
Regular ALA is racemic — a 50/50 mix of R-isomer and S-isomer. Only R-ALA is biologically active in human metabolism. Buying racemic ALA at 600 mg means you are getting roughly 300 mg of active drug. R-ALA or sodium R-lipoate at 300 mg gives you the same active dose at a smaller pill size. For long-term use, sodium R-lipoate (Na-RALA) is the most stable form.Can alpha-lipoic acid help with weight loss?
Modestly. The Kucukgoncu 2017 meta-analysis of 10 RCTs found a 1.27 kg greater weight loss versus placebo over 2–24 weeks. Statistically real, clinically minor — that's a tail benefit, not a weight-loss strategy. Caloric deficit and exercise drive the actual weight outcomes; ALA contributes a few pounds at the margin.Will it lower my blood sugar?
If you have type 2 diabetes or metabolic syndrome, yes — modestly. The Akbari 2018 meta-analysis of 24 RCTs found significant reductions in fasting glucose, insulin, HOMA-IR, and HbA1c. Effect is smaller than first-line drugs like metformin. If you are already on diabetic medication, monitor your glucose closely when starting ALA — the effects stack and hypoglycemia is real.When should I take alpha-lipoic acid?
On an empty stomach — at least 30 minutes before food or 2 hours after. Food cuts absorption by roughly half, and the clinical-trial doses all assume fasted dosing. Morning, mid-afternoon, or right before bed all work. Pair the timing with your medications (separate from levothyroxine by at least 4 hours).Is alpha-lipoic acid safe long-term?
NATHAN 1 ran ALA at 600 mg/day for 4 years with a clean safety profile — that's the longest dataset we have. Two long-term flags: (1) ALA competes with biotin at gut transporters, so long-term users should add 30–100 mcg biotin daily, and (2) rare but documented insulin autoimmune syndrome (Hirata disease) reports exist, more common in East Asian populations carrying HLA-DR4.
References
- 01Examine.com — Alpha-Lipoic Acid
- 02NIH Office of Dietary Supplements — Alpha-Lipoic Acid (LPI Micronutrient Center)
- 03StatPearls — Alpha-Lipoic Acid (NCBI Bookshelf)
Last reviewed2026-05-07